BLFS
BioLife Solutions Inc
38.50$
-0.3%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +0.4% | -2.7% | -6.6% | +1.8% | +4.7% | -1.1% | -2.0% | +1.3% | +3.5% | -1.2% | +11.6% | |
| – | +3.2% | -7.4% | -21.0% | +1.3% | +66.4% | -11.9% | -4.3% | +0.9% | +7.9% | -2.4% | +1.5% | |
| – | +45.0% | +6.6% | -25.9% | +8.9% | +297.8% | -29.8% | -52.3% | -7.6% | +12.1% | -30.9% | +5.1% | |
| – | +7.7% | +2.5% | -24.7% | +0.2% | +205.9% | -15.3% | -7.7% | -3.4% | +12.6% | -8.9% | +1.8% | |
| – | -24.0% | -0.4% | -2.7% | -0.8% | -48.8% | 0.0% | +9.7% | +7.8% | -26.6% | +64.2% | -18.4% | |
| – | +0.2% | -0.1% | -25.1% | -1.0% | -9.8% | -5.0% | +0.4% | +0.5% | +8.4% | +8.9% | +8.4% | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | -5.5% | +0.0% | +0.0% | +0.0% | -1.8% | +0.0% | +0.0% | |
| – | -4.1% | -4.3% | -4.5% | -4.7% | -48.1% | -7.3% | -8.0% | -8.6% | -42.9% | -7.6% | -7.1% | |
| – | -5.2% | -9.1% | -21.5% | +5.0% | -10.0% | -15.9% | -5.7% | -4.3% | -11.3% | -15.6% | -4.1% | |
| – | -1.0% | -8.3% | -20.3% | +4.4% | +1.8% | -15.3% | +2.1% | -4.1% | -15.4% | -20.6% | -23.6% | |
| – | -9.2% | +53.4% | +15.7% | +14.2% | -18.8% | -1.4% | -0.5% | -20.8% | -25.1% | -33.5% | -46.1% | |
| – | -42.1% | -28.2% | -15.5% | -8.9% | -6.9% | -7.7% | -2.7% | -9.9% | -48.6% | +152.4% | -33.8% | |
| – | -12.5% | -14.4% | -33.4% | -25.1% | -36.1% | -50.0% | – | – | – | – | – | |
| – | +1.7% | -1.3% | -3.6% | +1.3% | +7.2% | +1.1% | -1.6% | +1.9% | +5.1% | +0.1% | +12.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.2% | +4.1% | +1.3% | +0.4% | +4.0% | -1.9% | +1.4% | +1.9% | -0.2% | +1.2% | +0.1% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.